About this condition
Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome is a complex endocrine disorder characterized by hyperandrogenism (elevated androgens), ovulatory dysfunction, and polycystic ovarian morphology. PCOS affects approximately 6-20% of reproductive-age women depending on diagnostic criteria and population studied, making it one of the most common endocrine disorders. The condition presents with variable phenotypes: some women experience irregular periods and infertility; others have severe hirsutism, acne, and male-pattern baldness; many develop metabolic dysfunction including insulin resistance, dyslipidemia, and increased cardiovascular risk. Diagnosis relies on clinical and ultrasonographic criteria (Rotterdam criteria, NIH criteria), not genetic testing. The etiology is multifactorial, involving genetic predisposition combined with environmental factors (diet, exercise, stress) and primary pathophysiology centered on insulin resistance and abnormal androgen synthesis.
PCOS has a complex polygenic architecture identified through genome-wide association studies (GWAS), with more than 11 independent susceptibility loci identified to date. The genes at these loci include DENND1A (involved in intracellular trafficking), THADA (involved in metabolic and thyroid function), and INSR (the insulin receptor, the primary sensor of insulin signaling). Each locus carries individual effect sizes measured in odds ratios of 1.05-1.2 per allele — tiny effects individually but cumulatively contributing to disease susceptibility. Importantly, these are susceptibility loci, not disease-causing genes; the vast majority of carriers of risk alleles do not develop PCOS, and many PCOS patients lack multiple risk alleles, highlighting the substantial role of environmental factors.
Genetic understanding of PCOS has shifted clinical perspective from viewing PCOS as primarily a reproductive disorder to recognizing its deep metabolic underpinnings. The strong association of insulin resistance with PCOS and the identification of INSR variants as susceptibility loci has driven therapeutic research targeting the insulin pathway. While individual genetic testing cannot yet predict PCOS development, understanding the genetic basis has identified therapeutic targets and enabled development of PCOS-specific interventions. Future polygenic risk score models may enable personalized risk assessment and preventive intervention in at-risk women identified through family history or genetic screening.
- Gene locus
- DENND1A (2q41.2), THADA (2p21), INSR (19p13.2)
